Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study

Jin Yang¹, Ran Zeng¹, Jianping Zhou¹,²,³, Lifeng Luo¹,⁴, Mengchen Lyu¹, Fang Liu¹,⁵, Xianwen Sun¹,²,³, Ling Zhou¹,²,³, Xiaofei Wang¹,²,³, Zhiyao Bao¹,²,³, Wei Chen¹,²,³, Daphne W. Dumoulin⁶, Beili Gao¹,²,³, Yi Xiang¹,²,³

¹Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; ²Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China; ³Shanghai Key Laboratory of Emergency Prevention, Diagnosis, and Treatment of Respiratory Infectious Diseases, Shanghai, China; ⁴Department of Respiratory Disease, Kashgar Prefecture Second People’s Hospital, Kashi, China; ⁵Department of Oncology, Shanghai Huangpu District Cancer Prevention and Treatment Hospital, Shanghai, China; ⁶Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Contributions: (I) Conception and design: B Gao, Y Xiang; (II) Administrative support: B Gao, Y Xiang; (III) Provision of study materials or patients: J Zhou, X Sun, L Zhou, Z Bao, W Chen; (IV) Collection and assembly of data: J Yang, R Zeng, L Luo, F Liu, M Lyu; (V) Data analysis and interpretation: J Yang, R Zeng; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*These authors contributed equally to this work and should be considered as co-first authors.

Background: The rechallenge of immune checkpoint inhibitors (ICI) is now an optional strategy for patients who discontinued ICI due to immune-related adverse events (irAEs) or disease progression. However, little data is available for the prognosis and prognostic factors of patients receiving ICI rechallenge treatment in advanced lung cancer patients. Our study aimed to explore the efficacy, prognosis and safety of patients who received anti-programmed cell death-1/programmed cell death ligand 1 (anti-PD-1/PD-L1) inhibitor rechallenge.

Methods: In our retrospective cohort study, data of advanced lung cancer patients who received anti-PD-1/PD-L1 inhibitor and discontinued due to irAEs or disease progression were collected from December 2016 to August 2021. Enrolled patients were categorized into two groups: rechallenge group (R group) and non-rechallenge group (NR group). Progression-free survival (PFS), overall survival (OS), disease control rate (DCR) and safety data were analyzed. Cox model and subgroup analysis were analyzed according to baseline characteristics, ICI type, the reason for discontinuing ICI, etc. According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), evaluation was performed routinely every 6–8 weeks after initiating treatment with the PD-1/PD-L1 inhibitor. The last follow-up in the study was on September 20, 2021.

Results: Eighty-one patients who met our inclusion criteria were enrolled. In the whole cohort, the R group achieved better OS than the NR group (hazard ratio (HR) = 0.176; 95% confidence interval (CI): 0.065–0.477; P=0.001). In the irAEs group, the survival analyses showed a trend toward improved OS in the rechallenge subgroup (HR = 0.287; 95% CI: 0.081–1.025; P=0.055), and a promising DCR of 75% after an ICI rechallenge. Additionally, the exploration of safety outcomes indicated an acceptable recurrence rate (22.5%) of irAEs and an early onset of irAEs after an ICI rechallenge. In the disease progression group, the rechallenge subgroup did not improve OS (HR = 0.214; 95% CI: 0.027–1.695; P=0.144), and the DCR of the rechallenge subgroup was 40% after ICI rechallenge.

Conclusions: ICI rechallenge might be an attractive option for patients who discontinue treatment due to irAEs. For patients with disease progression, further research should be conducted. The recurrence of irAEs and their early onset during the second round of ICI should be considered.
Introduction

In recent years, immune checkpoint inhibitor (ICI) has completely changed the treatment pattern of advanced lung cancers (1). A previous study has shown that the activation of immune checkpoints, such as the programmed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1) signaling pathway, can attenuate the antitumor ability of cytotoxic T cells and lead to an immunosuppressive tumor microenvironment, which contributes to tumor immune escape. Anti-PD-1/PD-L1 inhibitors can hamper the immune escape of tumor cells and enhance the body’s endogenous antitumor activities (2).

Pembrolizumab (an anti-PD-1 inhibitor) was approved as a second-line treatment for advanced non-small-cell lung cancer (NSCLC) by the U.S. Food and Drug Administration in 2015; since then, several anti-PD-1/PD-L1 inhibitors have shown promising antitumor effects against lung cancers (3). Despite the considerable clinical benefits of ICIs in lung cancer patients, some patients discontinue ICIs due to disease progression, toxicity, or completion of a fixed treatment course (4,5). To achieve better clinical outcomes of ICIs in these patients, ICI rechallenge, using the same or another ICI after the initial discontinuation, has attracted much attention in clinical practice (6-8).

For advanced lung cancer patients who have benefited from initial ICI and discontinued ICI owing to irAEs, clinicians and patients tended to reuse ICIs to make full of their efficacy after irAEs were relieved. Patients who discontinued ICI owing to disease progression tend to ICI rechallenge according to philanthropic projects and the lack of new treatment strategies. However, strong concerns about the effectiveness and the recurrence of irAEs during the second round of ICI have hindered the application of rechallenge. Furthermore, there were no high-quality evidence of whether patients with disease progression would benefit from the retreatment of ICI. The efficacy-safety balance of immunotherapy rechallenge in lung cancer patients has not yet been fully clarified. Thus, we investigated the efficacy, clinical outcomes and safety outcomes of patients who discontinued anti-PD-1/PD-L1 inhibitors due to irAEs or disease progression and subsequently received additional ICI at a later date. We present the following article in accordance with the STROBE reporting checklist (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-360/rc).

Methods

In this cohort study, we analyzed the overall survival (OS) in the rechallenge group (R group) as well as in the non-rechallenge group (NR group) according to the reason for discontinuing ICI. We used subgroup analyses to explore the potential risk factors for clinical outcomes and safety. We evaluated the therapeutic effect in initial and subsequent ICI according to the reason for discontinuation.

Study design and patient enrollment

The flowchart of the study design is presented in Figure 1. Clinical data of patients with advanced lung cancers who were hospitalized in the Department of Respiratory and Critical Care Medicine of Ruijin Hospital between December 2016 and August 2021 were collected.

Patients who met the following criteria were enrolled: (I) pathologically confirmed lung cancer; (II) previously received anti-PD-1/PD-L1 inhibitor treatment; (III)
discontinued anti-PD-1/PD-L1 inhibitor treatment owing to disease progression or irAE; (IV) data were available for evaluation; (V) had a diagnosis of advanced-stage cancer according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.

Enrolled patients were categorized into two groups according to the following definitions: (I) the R group (n=45): patients who discontinued anti-PD-1/PD-L1 inhibitors for more than 3 weeks and subsequently received anti-PD-1/PD-L1 inhibitors again; and (II) the NR group (n=36): patients who did not retreated with anti-PD-1/PD-L1 inhibitors. Patients were divided into two groups according to the reasons for discontinuation: the irAE group (R1 group, n=40; NR1 group, n=17) and the disease progression group (R2 group, n=5; NR2 group, n=19).

This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013), and the protocol was reviewed and approved by the institutional review board of Ruijin Hospital (Approval No. 2019-72). Individual consent for this retrospective analysis was waived.

**Data collection and evaluation**

Patient data included sex, age, smoking status, Eastern Cooperative Oncology Group performance status (ECOG PS), clinical stage according to AJCC staging system (the 8th edition), PD-L1 tumor proportion score (TPS), status of metastasis, date of diagnosis, pathological type, therapeutic regimen, and reason for discontinuation.

We assessed and categorized clinical efficacy as either complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD), according to the revised RECIST guidelines (version 1.1) (14). The ORR was defined as the percentage of patients with CR and PR. The disease control rate (DCR) was the percentage of patients who achieved CR, PR, or SD. As far as such information bias is concerned, the imaging evaluations of the patients are individually evaluated by two imaging investigators. In case of different imaging evaluations, an internal discussion was planned to unify the assessment.

OS was defined as the time from the first dose of an anti-PD-1/PD-L1 inhibitor to death from any cause. The last follow-up in the study was on September 20, 2021. During the follow-up, evaluation was performed routinely every 6–8 weeks after starting treatment with the PD-1/PD-L1 inhibitor. For patients not admitted to Ruijin hospital subsequently, we obtained the patient’s survival status through phone calls and on-site visits.

As shown in Figure 2, in the R1 group, progression-free survival (PFS)1 was calculated from the 1st day of the first ICI administration to the start of the second ICI treatment, and PFS2 was calculated from the start of the second ICI treatment to tumor progression or death from any cause. In the NR1 group, PFS1 was calculated from the 1st day of the first ICI administration to the start of another therapy or the end of the initial ICI treatment.
from the end of the initial ICI treatment to tumor progression or death from any cause. In the R2 and NR2 groups, PFS1 was calculated from the start of the first ICI treatment to tumor progression, and PFS2 was calculated from the start of the second ICI treatment or another therapy to tumor progression or death from any cause. Total PFS is the cumulative value of PFS1 and PFS2.

The diagnosis of irAE was confirmed by a multidisciplinary team in Ruijin Hospital. The irAE grade was evaluated according to the fifth Common Toxicity Criteria for Adverse Events (CTCAE) classification (version 5.0).

Statistical analysis

Baseline characteristics are presented as the median and interquartile range (IQR) for continuous variables and the frequency and percentage for categorical variables. For patients with missing data, we defined them as unknown when grouping. Our missing data analysis procedures used missing completely at random (MCAR) assumptions. If the patient was lost to follow-up, we considered the last day in the hospital as the time of his death. In statistical analysis, we set the survival time of patients who were lost to follow-up as a cutoff value. PFS and OS were calculated using the Kaplan-Meier method, and differences were compared using the log-rank test. The OS rate was calculated using SPSS 24.0 (IBM, Armonk, NY, USA). Univariate and multivariate Cox regression analyses were performed to identify predictors of OS. Factors that might be associated with OS risk in the univariate analysis (P<0.050) were included in the multivariate Cox regression analysis. A two-tailed P value <0.050 was considered statistically significant. Graphs were drawn using R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Patient population and clinical characteristics

Between December 2016 and August 2021, 405 patients with lung cancer receiving ICI were hospitalized in the Department of Respiratory and Critical Care Medicine of Ruijin Hospital. Of these patients, 85 patients met our inclusion criteria, but 3 patients had no baseline information and one patient was lost to follow up after receiving one cycle treatment. A total of 81 patients who met our inclusion criteria were enrolled in this study. The baseline characteristics are shown in Table 1. Regarding the reason for ICI discontinuation, 40 patients in the R group stopped anti-PD-1/PD-L1 inhibitors because of irAEs (R1 group), and 5 patients stopped because of disease progression (R2 group). In the NR group, 17 patients stopped treatment because of irAEs (NR1 group), and 19 stopped because of disease progression (NR2 group). An overview of the duration of the R groups is presented in Figure 3.

Efficacy evaluation

The median follow-up of this study was 14.5 months.
Fourteen patients in the R group and nine patients in the NR group lost to follow up. Patients in the R group had a better OS compared to those in the NR group [not reached vs. 14.56 months; hazard ratio (HR) = 0.176; 95% confidence interval (CI): 0.065–0.477; P = 0.001; Figure 4A]. Although statistical significance was not obtained, there was a trend toward better OS in the R1 group (not reached vs. 18.667 months; HR = 0.287; 95% CI: 0.081–1.025; P = 0.055; Figure 4B). No difference in OS between the R2 group and the NR2 group was observed (not reached vs. 12.3 months; HR = 0.214; 95% CI: 0.027–1.695; P = 0.144; Figure 4C).

According to the Cox univariate analysis of the whole cohort (Table 2), several clinical characteristics were associated with OS, including discontinuation due to disease progression (HR = 3.923; 95% CI: 1.645–9.355; P = 0.002), distant metastasis (HR = 3.752; 95% CI: 1.379–10.212; P = 0.010), brain metastasis (HR = 3.662; 95% CI: 1.527–8.781; P = 0.004), and anti-PD-1/PD-L1 inhibitor rechallenge (HR = 0.176; 95% CI: 0.065–0.477; P = 0.001).

After entering the above significant factors (P ≤ 0.05) into the multivariate model, we found that receiving anti-PD-1/PD-L1 inhibitor rechallenge was an independent OS-related factor (HR = 0.155; 95% CI: 0.031–0.817; P = 0.022). Patients who received anti-PD-1/PD-L1 inhibitor rechallenge had an 84.5% lower risk of death. The subgroup analysis showed that the R group received more clinical benefits than the NR group. As shown in Figure 5, the following factors were associated with clinical benefit: R group (HR = 0.176; 95% CI: 0.065–0.477), male (HR = 0.221; 95% CI: 0.075–0.650), PD-L1 ≥ 1% (HR = 0.123; 95% CI: 0.025–0.597), NSCLC (HR = 0.239; 95% CI: 0.086–0.667), IV stage (HR = 0.155; 95% CI: 0.045–0.533), never smoked (HR = 0.080; 95% CI: 0.010–0.627), past and current smoking status (HR = 0.252; 95% CI: 0.074–0.864), non-first-line ICI therapy (HR = 0.122; 95% CI: 0.057–0.260), PS 0–1 (HR = 0.182; 95% CI: 0.066–0.501), and combined other therapy (HR = 0.203; 95% CI: 0.073–0.566).

The median PFS was not reached in the R1 group and was 15.4 (95% CI: 13.904–16.963) months in the NR1 group. The HR in the NR1 group vs. the R1 group was 0.484 (95% CI: 0.190–1.232; P = 0.144; Figure 6A). No difference in PFS between the R2 group and NR2 group was observed (7.1 vs. 10.2 months; HR = 1.047; 95% CI: 0.328–3.345; P = 0.938; Figure 6B). The median PFS2 of the R2 group was 3.2 (95% CI: 0–9.849) months. The median

### Table 1 General characteristics of the study population

| Characteristics                  | Patients, n (%)                        |
|----------------------------------|---------------------------------------|
|                                 | Rechallenge (n=45) | Non-rechallenge (n=36) |
| Median age [IQR] (years)         | 65 [60–71]          | 63 [57.25–68.50]        |
| Sex                              |                        |                        |
| Male                             | 41 (91.1)             | 25 (69.4)               |
| Female                           | 4 (8.9)               | 11 (30.6)               |
| ECOG PS                          |                        |                        |
| 0–1                              | 41 (91.1)             | 32 (88.9)               |
| ≥2                               | 4 (8.9)               | 4 (11.1)                |
| Stage                            |                        |                        |
| III                              | 18 (40.0)             | 7 (19.4)                |
| IV                               | 27 (60.0)             | 29 (80.6)               |
| Distant metastasis               |                        |                        |
| Yes                              | 25 (55.6)             | 11 (30.6)               |
| No                               | 20 (44.4)             | 25 (69.4)               |
| Pathology                        |                        |                        |
| Squamous carcinoma               | 8 (17.8)              | 4 (11.1)                |
| Adenocarcinoma                   | 26 (57.8)             | 28 (77.8)               |
| Small-cell lung cancer           | 8 (17.8)              | 4 (11.1)                |
| Other†                           | 3 (6.7)               | 0 (0.0)                 |
| Smoking status                   |                        |                        |
| Never                            | 13 (28.9)             | 17 (47.2)               |
| Past and current                 | 32 (71.1)             | 19 (52.8)               |
| PD-L1 TPS (%)                    |                        |                        |
| Negative                         | 6 (13.3)              | 2 (5.6)                 |
| 1–50                             | 8 (17.8)              | 13 (36.1)               |
| ≥50                              | 12 (26.7)             | 4 (11.1)                |
| Unknown                          | 19 (42.2)             | 17 (47.2)               |
| Initial immunotherapy            |                        |                        |
| Anti-PD-1†                       | 37 (82.2)             | 34 (94.4)               |
| Anti-PD-L1§                      | 8 (17.8)              | 2 (5.6)                 |
| Number of ICI rounds             |                        |                        |
| 1                                | 20 (44.4)             | 15 (41.7)               |
| ≥2                               | 25 (55.6)             | 21 (58.3)               |
| Discontinuation reason           |                        |                        |
| Disease progression              | 5 (11.1)              | 17 (47.2)               |
| IrAEs                            | 40 (88.9)             | 19 (52.8)               |

†, other, poorly differentiated carcinoma; ‡, anti-PD-1, nivolumab, pembrolizumab, camrelizumab, tsiluzumab, sintiluzumb, toripalimab; §, anti-PD-L1, atezolizumab, durvalumab. IQR, interquartile range; ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed cell death ligand 1; TPS, tumor proportion score; PD-1, programmed cell death-1; ICI, immune checkpoint inhibitor; irAEs, immune-related adverse events.
Figure 3 Overview of the duration of the R group. ICI, immune checkpoint inhibitor; SD, stable disease; PR, partial response; PD, progressive disease; R group, rechallenge group.

Figure 4 Kaplan-Meier curves for OS. (A) NR vs R groups (B) NR1 vs. R1 groups; (C) NR2 vs. R2 groups. R group, patients who discontinued anti-PD-1/PD-L1 inhibitor for more than 3 weeks and subsequently received anti-PD-1/PD-L1 inhibitor again; NR group, patients who did not receive rechallenge with anti-PD-1/PD-L1 inhibitor. According to the reasons for discontinuation, patients were divided into two groups: irAE group (R1 and NR1 groups) and disease progression group (R2 and NR2 groups). OS, overall survival; CI, confidence interval; HR, hazard ratio; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand 1; R group, rechallenge group; NR group, non-rechallenge group; irAEs, immune-related adverse events.
### Table 2 Univariate and multivariate analysis of OS in whole group

| Factors                                      | Univariate analysis | Multivariate analysis |
|----------------------------------------------|---------------------|-----------------------|
|                                              | HR (95% CI)         | P value               | HR (95% CI)         | P value               |
| Group                                        |                     |                       |                     |                       |
| Non-rechallenge                              | 1                   | 1                     | 1                   | 1                     |
| Rechallenge                                  | 0.176 (0.065–0.477) | 0.001                 | 0.155 (0.031–0.817) | 0.022                 |
| The reason of disrupt first ICI              |                     |                       |                     |                       |
| IrAEs                                        | 1                   |                       | 1                   |                       |
| Disease progression                          | 3.923 (1.645–9.355) | 0.002                 |                     |                       |
| Sex                                          |                     |                       |                     |                       |
| Male                                         | 1                   | 1.799 (0.732–4.418)   | 0.200               |                       |
| Female                                       |                     |                       |                     |                       |
| Age (years)                                  |                     |                       |                     |                       |
| <65                                          | 1                   |                       | 1                   |                       |
| ≥65                                          | 1.476 (0.631–3.413) | 0.374                 |                     |                       |
| Smoking statue                               |                     |                       |                     |                       |
| Never                                        | 1                   |                       | 1                   |                       |
| Past and current                             | 0.503 (0.232–1.191) | 0.082                 |                     |                       |
| PD-L1 TPS (%)                                |                     |                       |                     |                       |
| <1                                           | 1                   |                       | 1                   | 0.222                 |
| 1–49                                         | 2.103 (0.427–10.365) |                       |                     |                       |
| ≥50                                          | 2.502 (0.946–6.618) |                       |                     |                       |
| Unknown                                      | 0.841 (0.175–4.051) |                       |                     |                       |
| Clinical stage                               |                     |                       |                     |                       |
| III                                          | 1                   |                       | 1                   |                       |
| IV                                           | 3.022 (0.892–10.233) | 0.076                 |                     |                       |
| Distant metastasis                           |                     |                       |                     |                       |
| No                                           | 1                   |                       | 1                   |                       |
| Yes                                          | 3.752 (1.379–10.212) | 0.010                 |                     |                       |
| Pathology                                    |                     |                       |                     |                       |
| Small cell lung cancer                       | 1                   |                       | 1                   |                       |
| NSCLC                                        | 0.933 (0.275–3.167) | 0.912                 |                     |                       |
| Brain metastasis                             |                     |                       |                     |                       |
| No                                           | 1                   |                       | 1                   |                       |
| Yes                                          | 3.662 (1.527–8.781) | 0.004                 | 0.437 (0.026–7.460) | 0.568                 |
| Line of receiving first ICIs                 |                     |                       |                     |                       |
| 1                                            | 1                   |                       | 1                   |                       |

Table 2 (continued)
Table 2 (continued)

| Factors                          | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR (95% CI)         | P value               | HR (95% CI) | P value               |
| ≥2                               | 2.775 (0.761–10.117) | 0.122                 | 2.816 (0.271–29.216) | 0.386               |
| ICIs type                        |                     |                       |             |                       |
| PD-1                             |                     |                       |             |                       |
| PD-L1                            | 1.359 (0.580–3.182)  | 0.819                 |             |                       |
| Combined treatment                |                     |                       |             |                       |
| No                               |                     |                       |             |                       |
| Yes                              | 0.577 (0.194–1.712)  | 0.321                 |             |                       |

Anti-PD-1: nivolumab, pembrolizumab, camrelibuzumab, tisitolizumab, sintilizumab, toripalimab; anti-PD-L1: atezolizumab, durvalumab. OS, overall survival; irAE, immune-related adverse event; PD-L1, programmed cell death ligand 1; TPS, tumor proportion score; NSCLC, non-small-cell lung cancer; ICIs, immune checkpoint inhibitors; PD-1, programmed cell death-1; HR, hazard ratio; CI, confidence interval.

Table 2

| Variables                              | Non-rechallenge Group | Rechallenge Group | P value | HR (95% CI) |
|----------------------------------------|-----------------------|-------------------|---------|--------------|
|                                        | No of survival >1 year | OS rate 95% CI    |         |              |
| Sex                                    |                       |                   |         |              |
| Male                                   | 11 (23)               | 0.72 (0.41–0.96)  | 0.001   | 0.176 (0.060, 0.474) |
| Female                                 | 15                    | 0.69 (0.49–1.00)  | 0.24    | 0.022 (0.000, 13.04) |
| Age                                    |                       |                   |         |              |
| <65 Y                                  | 10 (23)               | 0.71 (0.52–0.97)  | 0.001   | 0.039 (0.004, 0.85)  |
| ≥65 Y                                  | 36                    | 0.72 (0.49–1.00)  | 0.004   | 0.350 (0.102, 1.197) |
| Smoking status                         |                       |                   |         |              |
| Never                                  | 9 (17)                | 0.78 (0.57–1.00)  | 0.016   | 0.660 (0.010, 0.627) |
| Never and current                      | 30                    | 0.66 (0.46–0.96)  | 0.028   | 0.252 (0.074, 0.864) |
| PD-L1 TPS (%)                          |                       |                   |         |              |
| ≤1                                     | 4 (10)                | 0.75 (0.46–1.00)  | 0.379   | 0.379 (0.017, 4.715) |
| >1                                     | 33                    | 0.57 (0.32–1.00)  | 0.009   | 0.123 (0.025, 0.597) |
| Not quantifiable/reportable            | 34                    | 0.81 (0.63–1.00)  | 0.036   | 0.107 (0.013, 0.886) |
| Pathology                              |                       |                   |         |              |
| Small cell lung cancer                 | 12                    | 0.5 (0.188–1.00)  | 0.343   | 0.005 (0.0, 295.42)  |
| Non-small cell lung cancer             | 69                    | 0.74 (0.582–0.949)| 0.006   | 0.239 (0.096, 0.667) |
| Clinical stage                         |                       |                   |         |              |
| I                                       | 25                    | 4 (7) NA NA       | 0.063   | 0.521 (0.045, 6.076) |
| IV                                     | 56                    | 0.65 (0.475–0.882)| 0.003   | 0.159 (0.045, 0.533) |
| Brain metastasis                       |                       |                   |         |              |
| No                                      | 50                    | 0.86 (0.63–1.00)  | 0.133   | 0.250 (0.041, 1.527) |
| Yes                                     | 31                    | 0.64 (0.45–0.989)| 0.233   | 0.030 (0.000, 8.482) |
| ICIs type                              |                       |                   |         |              |
| PD-1                                   | 71                    | 0.73 (0.571–0.927)| 0.001   | 0.597 (0.199, 17.96) |
| Line of receiving first ICIs            |                       |                   |         |              |
| 1                                       | 46                    | 0.74 (0.522–1.00)| 0.059   | 0.800 (0.869, 1.051) |
| ≥2                                      | 35                    | 0.76 (0.56–0.989)| 0.007   | 0.122 (0.027, 0.560) |
| Performance status                     |                       |                   |         |              |
| 0–1                                     | 73                    | 0.72 (0.564–0.924)| 0.001   | 0.182 (0.066, 0.517) |
| 2                                       | 8                     | 0.67 (0.300–1.000)| 0.002   | 0.203 (0.073, 0.556) |
| Combined treatment                      |                       |                   |         |              |
| No                                      | 11                    | 0.64 (0.338–1.00)| 0.577   | 0.520 (0.052, 5.162) |
| Yes                                     | 70                    | 0.73 (0.569–0.946)| 0.002   | 0.203 (0.073, 0.556) |

Figure 5 Multivariable analysis of OS in R and NR groups. PD-L1, programmed cell death ligand 1; TPS, tumor proportion score; ICIs, immune checkpoint inhibitors; PD-1, programmed cell death 1 inhibitor; irAEs, immune-related adverse events; OS, overall survival; NA, not available; CI, confidence interval; HR, hazard ratio; R group, rechallenge group; NR group, non-rechallenge group.
PFS2 of the rechallenge patients was 1.6 (95% CI: 0.383–2.817) months. The HR for the NR2 group vs. the R2 group was 0.231 (95% CI: 0.632–6.726; P=0.219; Figure 6D).

We also explored the anti-tumor response of rechallenge. Although the rechallenge did not present as good ORR and DCR as in the first use of anti-PD-1/PD-L1 inhibitors, a promising DCR of 75% in the R1 group was observed (Figure 7A). In the R2 group, no patients experienced a CR in initial and subsequent treatment. The DCR was 80% in the first ICI and 40% in the second ICI (Figure 7B).

**Safety of retreatment with ICIs after initial irAE**

Forty rechallenged patients experienced irAEs during the first ICI cycle. Specific details of the patients are given in Table S1. Among them, the most common irAE was immune-related pneumonitis (20/40). A total of 22.5% (9/40) of patients experienced irAEs during rechallenge, among which 5 patients experienced the same adverse reactions as before, while 4 patients experienced new irAEs (Figure 8). Among these 9 patients, only one suffered grade 3 irAEs, while the remaining 8 patients had grade 1–2 irAEs. The onset time of irAEs during the second cycle of ICI ranged from 10 to 120 days, with a median onset time of 21 days.

**Discussion**

The efficacy of anti-PD-1/PD-L1 inhibitors in lung cancer has been confirmed by multiple phase III clinical trials, such as Keynote-024 (15), Keynote-189 (16), and Checkmate 227 (17). Anti-PD-1/PD-L1 inhibitors have become promising options for treating advanced lung cancer patients in addition to targeted therapy, chemotherapy and radiotherapy (1). However, in clinical practice, some patients discontinue ICIs for various reasons, such as irAEs and disease progression. Previous studies have shown that...
worse clinical outcomes were observed in patients who discontinued ICIs than in continuously treated patients (18-21). Considering the durable anti-tumor effect of ICI rechallenge reported in several case reports (22-24), the clinical benefit of restarting ICI has received widespread consideration.

The efficacy and safety of ICI rechallenge were first explored in melanoma (25). Pollack et al. enrolled 80 melanoma patients who discontinued ICIs due to severe irAEs and showed high rates of recurrent or distinct toxicities (12).

Several studies evaluated the clinical outcomes and risk assessment of irAEs in ICI-retreated patients with lung cancer. Mouri et al. enrolled 187 nivolumab-treated patients who ceased treatment due to a serious irAE; the results indicated that retreatment had a slightly higher efficacy without a significant increase in irAEs (21). However, another study enrolled 133 patients and showed no survival benefit in the rechallenge and non-rechallenge groups (18). In addition, several studies have looked at patients with NSCLC who stopped ICIs because of disease progression. Watanabe et al. enrolled 14 patients and show DCR was 21.4% during the second ICI therapy (26). A study led by Katayama explored the relationship between clinical features and the effectiveness of ICI rechallenge in patients who stopped initial ICI after disease progression, poor ECOG-PS and low body mass index (BMI) at the time of intervention with ICI rechallenge were independent prognosis factors (27).

Notably, the definition of ICI rechallenge remains unclear. A narrow definition is the resumption of ICI after irAEs improve in patients who stopped treatment due to irAEs (28). A more general definition is the resumption of ICI in patients who stopped treatment for any cause, including the adjustment of specific drugs (29,30). Research has mainly focused on the narrow definition of ICI rechallenge. However, the general definition might better match complicated real-world clinical practice. Therefore, we included patients who discontinued anti-PD-1/PD-L1 inhibitors due to irAEs or disease progression and analyzed the efficacy, clinical outcomes and safety outcomes of patients.

Our study included 81 Chinese patients who stopped initial anti-PD-1/PD-L1 inhibitors because of irAEs or...
Our results indicated that improved clinical outcomes and tolerable safety could also be observed in Chinese patients treated with general ICI re-challenge.

We applied subgroup analysis to explore the potential factors associated with the clinical outcomes of rechallenge. Trends in favor of longer OS with the irAEs group were obtained in the R1 group, which was consistent with published studies (18-21). However, a similar result was not seen in the disease progression group, in which rechallenge did not improve the clinical outcomes (PFS and OS). We found heterogeneity in the clinical efficacy in patients who received anti-PD-1/PD-L1 inhibitors in the R2 group. As presented in Figure 3, patient 45 and patient 09 both suffered rapid progression during their first treatment. However, the difference between PFS2 was great, with 7 months for patient 45 and 1 month for patient 9. We reviewed the clinical records of these patients and found that patient 45 received anlotinib (an orally administered tyrosine kinase inhibitor that targets tumor angiogenesis) as his second-line therapy, while patient 9 received chemotherapy as her second-line therapy. Anlotinib can ameliorate the immuno-microenvironment by downregulating PD-L1 expression on vascular endothelial cells to inhibit tumor growth (31). Various therapeutic regimens might affect the antitumor efficacies of subsequent ICI. Therefore, the above exploration in the R2 group indicated that a second tumor biopsy to evaluate the tumor microenvironment might play an important role in the evaluation of ICI restart in these patients. Nevertheless, the clinical outcome of ICI rechallenge in disease progression patients remains to be explored through prospective clinical trials and multi-omics studies.

Long-term immune memory protection can be provided by ICI even in the withdrawal period, but this can also lead to some unpleasant irAEs: uncertain onset, repeat attacks, and progressive aggravation. These features increase concerns about the recurrence of irAEs among rechallenge patients. Regarding the incidence of irAEs among patients receiving ICI rechallenge, we found that the recurrence rate of irAEs was lower in our cohort than in the Santini cohort (22.5% vs. 52%), which might have been due to the short follow-up time in our study (32). In addition, 5 patients experienced the same adverse reactions as in their first-line ICI, while 4 patients experienced new types of irAEs. These findings highlight the necessity of exhaustive evaluation for any potential irAEs. In our cohort, the onset time of irAEs during the second round of ICI ranged from 10 to 120 days, with a median onset time of 21 days, which was much earlier than the general onset time of 1–3 months seen in previous reports. Among the 9 patients who developed irAEs during rechallenge, only one suffered grade 3 irAEs, while the remaining 8 patients had grade 1–2 irAEs, indicating the tolerable adverse effects of rechallenge.

To our knowledge, this study is the first to evaluate the efficacy and safety among Chinese patients treated with general ICI rechallenge. Our results showed that rechallenging with ICIs improved the clinical outcomes in patients treated with general ICI rechallenge. For patients who initially discontinue ICI treatment due to irAEs, ICI rechallenge may be an attractive option. However, further research is needed regarding patients who discontinue ICI due to disease progression. In addition, the recurrence of irAEs and the early onset of irAEs during the second round of ICI, especially within the first 2 retreatment cycles, should be considered.

Our study has several limitations. First, this was a retrospective, single-center study. Although there is possible selection bias, our practicing clinical group can provide a degree of real-world understanding of advanced lung cancer patients who receive anti-PD-1/PD-L1 inhibitor rechallenge. Second, the follow-up time was insufficient, but some of our results are consistent with previous studies, and new insights into ICI rechallenge were obtained. Despite these limitations, our results further enrich the clinical evidence for the efficacy and safety of anti-PD-1/PD-L1 inhibitor rechallenge among patients with advanced lung cancers. Therefore, the assessment of efficacy and safety of anti-PD-1/PD-L1 inhibitor rechallenge should be explored in larger sample sizes and future prospective clinical trials.

**Conclusions**

Rechallenge with ICIs improved the clinical outcomes of patients treated with general ICI rechallenge. ICI rechallenge should be considered as a subsequent treatment for patients who have previously discontinued ICI due to irAEs. For patients who discontinue ICI due to disease progression, the clinical value of using ICI again may be limited and heterogeneous, and further clinical studies are
needed to explore. In addition, the recurrence of irAEs and early onset of irAEs during the second round of ICI should be considered.

Acknowledgments

The authors appreciate the academic support from the AME Lung Cancer Collaborative Group.

Funding: This work was supported by the National Key R&D Program of China (Grant No. 2018YFC1311902), the Shanghai Key Discipline for Respiratory Diseases (No. 2017ZZ02014) and the National Natural Science Foundation of China (No. 81672271).

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-360/rc

Data Sharing Statement: Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-360/dss

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-360/coif). DWD reports receiving payment for lectures, presentations, speakers bureaus, manuscript writing or educational events by Roche, BMS, MSD, Pfizer and Astra Zeneca. The other authors have no conflicts of interest to declare.

Ethics Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013), and the protocol was reviewed and approved by the institutional review board of Ruijin Hospital (Approval No. 2019-72). Individual consent for this retrospective analysis was waived.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license).

See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer. Lancet 2021;398:535-54.
2. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov 2018;8:1069-86.
3. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol 2015;33:1974-82.
4. Pires da Silva I, Ahmed T, Reijers ILM, et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol 2021;22:836-47.
5. Zhao Q, Zhang J, Xu L, et al. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis. Front Immunol 2021;12:730320.
6. Waterhouse DM, Garon EB, Chandler J, et al. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. J Clin Oncol 2020;38:3863-73.
7. Robert C, Schadendorf D, Messina M, et al. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013;19:2232-9.
8. Abu-Sbeih H, Ali FS, Naqash AR, et al. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol 2019;37:2738-45.
9. Abou Alaiwi S, Xie W, Nassar AH, et al. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer 2020;8:e000144.
10. Amode R, Baroudjian B, Kowal A, et al. Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients. Melanoma Res 2017;27:110-5.
11. Herbst RS, Garon EB, Kim DW, et al. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1–Positive, Advanced Non–Small-Cell Lung Cancer in the
KEYNOTE-010 Study. J Clin Oncol 2020;38:1580-90.
12. Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 2018;29:250-5.
13. Ravi P, Mantia C, Su C, et al. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. JAMA Oncol 2020;6:1606-10.
14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
15. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33.
16. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:2078-92.
17. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2019;381:2020-31.
18. Albandar HJ, Fuqua J, Albandar JM, et al. Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not? Cancers (Basel) 2021;13:989.
19. Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol 2019;5:1310-7.
20. Li M, Sack JS, Rahma OE, et al. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer 2020;126:5088-97.
21. Mouri A, Kaira K, Yamaguchi O, et al. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. Cancer Chemother Pharmacol 2019;84:873-80.
22. Deng C, Yang M, Jiang H, et al. Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report. Front Oncol 2021;11:664809.
23. Lee DH, Armanious M, Huang J, et al. Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge. J Oncol Pharm Pract 2020;26:1544-8.
24. Hakozaki T, Okuma Y, Kashima J. Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report. BMC Cancer 2018;18:302.
25. Lipson EJ. Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. Oncoimmunology 2013;2:e23661.
26. Watanabe H, Kubo T, Ninomiya K, et al. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Jpn J Clin Oncol 2019;49:762-5.
27. Katayama Y, Shimamoto T, Yamada T, et al. Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. J Clin Med 2019;9:102.
28. Haanen J, Ernstoff M, Wang Y, et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer 2020;8:e000604.
29. Fujisaki T, Watanabe S, Ota T, et al. The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events. Front Oncol 2021;11:704475.
30. Schaden D, Ascierto PA, Haanen J, et al. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer 2019;121:144-53.
31. Liu S, Qin T, Liu Z, et al. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis 2020;11:309.
32. Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunol Res 2018;6:1093-9.

Cite this article as: Yang J, Zeng R, Zhou J, Luo L, Lyu M, Liu F, Sun X, Zhou L, Wang X, Bao Z, Chen W, Dumoulin DW, Gao B, Xiang Y. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study. Transl Lung Cancer Res 2022;11(6):1038-1050. doi: 10.21037/tlcr-22-360